Literature DB >> 18721116

Riluzole in psychiatry: a systematic review of the literature.

Carlos A Zarate1, Husseini K Manji.   

Abstract

BACKGROUND: The glutamate system seems to be an important contributor to the pathophysiology of mood and anxiety disorders. Thus, glutamatergic modulators are reasonable candidate drugs to test in patients with mood and anxiety disorders. Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent.
OBJECTIVE: To assess the potential risks and benefits of riluzole treatment in psychiatric patients.
METHODS: A PubMed search was performed using the keywords 'riluzole', 'inhibitor of glutamate release' and 'glutamatergic modulator' to identify all clinical studies and case reports involving riluzole in psychiatric patients. RESULTS/
CONCLUSION: Riluzole's side effect profile is favorable and preliminary results regarding riluzole for the treatment of severe mood, anxiety and impulsive disorders are encouraging.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18721116      PMCID： PMC2587133          DOI： 10.1517/17425255.4.9.1223

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN： 1742-5255            Impact factor:   4.481


  91 in total

1.  Riluzole-induced acute pancreatitis.

Authors:  L Rodrigo; M Moreno; S Calleja; V Mateos; R J Andrade; M I Lucena
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

2.  Methemoglobinemia due to riluzole.

Authors:  A Viallon; Y Page; J C Bertrand
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

3.  Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.

Authors:  G Schwartz; M G Fehlings
Journal:  J Neurosurg       Date:  2001-04       Impact factor: 5.115

4.  Reversible granulocytopenia in association with riluzole therapy.

Authors:  W A North; A M Khan; H T Yamase; J R Sporn
Journal:  Ann Pharmacother       Date:  2000-03       Impact factor: 3.154

5.  Neuroimaging studies of mood disorders.

Authors:  W C Drevets
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

6.  A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.

Authors:  K M Noh; J Y Hwang; H C Shin; J Y Koh
Journal:  Neurobiol Dis       Date:  2000-08       Impact factor: 5.996

7.  Effects of riluzole on N-methyl-D-aspartate-induced tyrosine phosphorylation in the rat hippocampus.

Authors:  A Peyclit; H Keita; P Juvin; P Derkinderen; F Jardinaud; D Rouellé; J Boczkowski; J M Desmonts; J A Girault; J Mantz
Journal:  Brain Res       Date:  2001-06-08       Impact factor: 3.252

8.  Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

Authors:  I Mizuta; M Ohta; K Ohta; M Nishimura; E Mizuta; S Kuno
Journal:  Neurosci Lett       Date:  2001-09-14       Impact factor: 3.046

9.  The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects.

Authors:  A Kniest; C Wiesenberg; B Weber; M Colla; I Heuser; M Deuschle
Journal:  Neuropsychobiology       Date:  2001       Impact factor: 2.328

10.  Riluzole inhibits the persistent sodium current in mammalian CNS neurons.

Authors:  A Urbani; O Belluzzi
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386
View more
  29 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

3.  Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.

Authors:  Hitoshi Sakurai; Christina Dording; Albert Yeung; Simmie Foster; Felipe Jain; Trina Chang; Nhi-Ha Trinh; Richard Bernard; Sean Boyden; Syed Z Iqbal; Samuel T Wilkinson; Sanjay J Mathew; David Mischoulon; Maurizio Fava; Cristina Cusin
Journal:  J Affect Disord       Date:  2019-07-02       Impact factor: 4.839

4.  A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.

Authors:  Mehdi Farokhnia; Maryam Sabzabadi; Hossein Pourmahmoud; Mohammad-Reza Khodaie-Ardakani; Seyed-Mohammad-Reza Hosseini; Habibeh Yekehtaz; Mina Tabrizi; Farzin Rezaei; Bahman Salehi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-09-08       Impact factor: 4.530

Review 5.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

6.  12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.

Authors:  Paul J Grant; Lisa A Joseph; Cristan A Farmer; David A Luckenbaugh; Lorraine C Lougee; Carlos A Zarate; Susan E Swedo
Journal:  Neuropsychopharmacology       Date:  2013-12-19       Impact factor: 7.853

Review 7.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

8.  Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.

Authors:  Ali Ghaleiha; Effat Mohammadi; Mohammad-Reza Mohammadi; Mehdi Farokhnia; Amirhossein Modabbernia; Habibeh Yekehtaz; Mandana Ashrafi; Elmira Hassanzadeh; Shahin Akhondzadeh
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

9.  Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.

Authors:  Chadi G Abdallah; Jeremy D Coplan; Andrea Jackowski; João R Sato; Xiangling Mao; Dikoma C Shungu; Sanjay J Mathew
Journal:  Neurosci Lett       Date:  2012-10-05       Impact factor: 3.046

10.  Exploring cross-talk between oxidative damage and excitotoxicity and the effects of riluzole in the rat cortex after exposure to methylmercury.

Authors:  Yu Deng; Zhaofa Xu; Bin Xu; Wei Liu; Yangang Wei; Yuehui Li; Shu Feng; Tianyao Yang
Journal:  Neurotox Res       Date:  2014-02-12       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.